Publications
Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
.
2016. First-in-Human Brain Imaging of [F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.. ACS Chem Neurosci. 10(6):2697-2702.
.
2019. .
2018. .
2014.
Identification of [F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.. J Med Chem. 61(4):1737-1743.
.
2018. Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
.
2017. Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.. Int Psychogeriatr. 26(5):703-7.
.
2014. Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.. J Cereb Blood Flow Metab. 35(7):1169-74.
.
2015. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
.
2015. In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
.
2018. In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.. Transl Neurodegener. 3(1):6.
.
2014. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
.
2019. .
2017.
Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study.. Neuroimage. 98:195-202.
.
2014. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
.
2019. .
2016.
MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.. Trends Neurosci. 37(11):629-41.
.
2014. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
.
2017. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
.
2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
.
2017. No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
.
2019. .
2019. Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
.
2017. .
2018. .
2014.